Search research articles
Contact Us
Filters
Showing results (111-120 of 253) with videos related to
Page
of 26
Sort By:
JAMA Network Open
|
October 21, 2021
Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma
Angie Mae Rodday, Theresa Hahn, Anita J Kumar, et al.
Cell Death & Disease
|
January 9, 2024
Characterizing influence of rCHOP treatment on diffuse large B-cell lymphoma microenvironment through in vitro microfluidic spheroid model
Matthew R Sullivan, Rachel P White, Dashnamoorthy Ravi, et al.
Leukemia & Lymphoma
|
March 5, 2014
The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era
Chadi Nabhan, Briseis Aschebrook-Kilfoy, Brian C-H Chiu, et al.
Leukemia
|
November 28, 2019
Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma
Dashnamoorthy Ravi, Saheli Sarkar, Sneha Purvey, et al.
American Journal of Hematology
|
March 14, 2022
Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma
Andrew M Evens, Justin S Brandt, Cody J Peer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 7, 2009
PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells
Savita Bhalla, Sriram Balasubramanian, Kevin David, et al.
Journal of Cancer Survivorship : Research and Practice
|
August 27, 2024
Survivorship preparedness and activation among survivors of lymphoma
Sharon L Manne, Shawna V Hudson, Dena O'Malley, et al.
British Journal of Haematology
|
April 26, 2014
Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study
Andrew M Evens, Mitchell R Smith, Izidore S Lossos, et al.
Blood
|
September 25, 2004
Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells
Andrew M Evens, Philip Lecane, Darren Magda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 23, 2012
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas
M Agulnik, J L Yarber, S H Okuno, et al.
Page
of 26
Search research articles
Search
Showing results (111-120 of 253) with videos related to
Sort By:
Page
of 26
JAMA Network Open
|
October 21, 2021
Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma
Angie Mae Rodday, Theresa Hahn, Anita J Kumar, et al.
Cell Death & Disease
|
January 9, 2024
Characterizing influence of rCHOP treatment on diffuse large B-cell lymphoma microenvironment through in vitro microfluidic spheroid model
Matthew R Sullivan, Rachel P White, Dashnamoorthy Ravi, et al.
Leukemia & Lymphoma
|
March 5, 2014
The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era
Chadi Nabhan, Briseis Aschebrook-Kilfoy, Brian C-H Chiu, et al.
Leukemia
|
November 28, 2019
Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma
Dashnamoorthy Ravi, Saheli Sarkar, Sneha Purvey, et al.
American Journal of Hematology
|
March 14, 2022
Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma
Andrew M Evens, Justin S Brandt, Cody J Peer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 7, 2009
PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells
Savita Bhalla, Sriram Balasubramanian, Kevin David, et al.
Journal of Cancer Survivorship : Research and Practice
|
August 27, 2024
Survivorship preparedness and activation among survivors of lymphoma
Sharon L Manne, Shawna V Hudson, Dena O'Malley, et al.
British Journal of Haematology
|
April 26, 2014
Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study
Andrew M Evens, Mitchell R Smith, Izidore S Lossos, et al.
Blood
|
September 25, 2004
Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells
Andrew M Evens, Philip Lecane, Darren Magda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 23, 2012
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas
M Agulnik, J L Yarber, S H Okuno, et al.
Page
of 26